United States of America (A3KLWF) Historical

Immunic Therapeutics chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company's strong presence at the 10th annual ACTRIMS Forum, where it presented two key posters on multiple sclerosis (MS). He highlighted that Immunic’s investigational drug, vidofludimus calcium, has potential neuroprotective properties that may benefit both relapsing and progressive MS patients. One of the posters examined baseline characteristics of past progressive MS trials and contrasted them with Immunic’s CALLIPER trial, designed for non-relapsing patients with minimal inflammatory activity. The second poster explored preclinical data on the drug’s mechanism of action, emphasizing its potential to target activated microglia and support neuron survival. Muehler noted significant engagement from the MS community at ACTRIMS, with many keenly anticipating the CALLIPER trial’s readout in April. “It’s really one of the very few late-stage drugs with a potential neuroprotective effect,” he said, adding that the data could provide new hope for progressive MS patients who currently have limited treatment options. Stay tuned for more updates on Immunic’s progress. For more interviews, subscribe to Proactive’s YouTube channel, like this video, and turn on notifications! #ImmunicTherapeutics #MSResearch #Neuroprotection #CALLIPERTrial #MultipleSclerosis #Biotech #DrugDevelopment #ClinicalTrials #MedicalBreakthrough #ACTRIMS

Wedgemount Resources CEO Mark Vanry joined Steve Darling from Proactive to provide an update to Proactive on the company's field activities at its recently acquired Huggy Assets. After weather-related delays, Wedgemount has full operations going, including pumping, surface facility optimization, maintenance, chemical treatments, and well workovers. The company's primary focus remains on the Echo and Novice operational areas, where five additional wells have been brought back online. These wells had been inactive for a significant period before Wedgemount's acquisition. Historical initial production (IP) rates for these wells ranged from 15 to 65 barrels of oil equivalent per day (boepd). Vanry noted that previous successful chemical stimulations on Wedgemount’s Willowbend leases resulted in improved well performance. The company expects similar or better results from workovers and chemical treatments at Huggy, potentially exceeding the original IP rates. Looking ahead, Wedgemount has over 100 additional wells that have yet to undergo chemical stimulation, presenting significant production upside over the next two years. #proactiveinvestors #westmountreosurcescorp #cse #wdgy #otcqb #wdgrf #OilProduction #TexasEnergy #EnergyInvesting #OilandGas #MarkVanry #ProactiveInvestors #EnergyStocks #Investing #OilExploration

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy joined Proactive's Stephen Gunnion with details about the company's latest milestone—the successful prototyping of its 50Ah Goliath EV battery. This marks a significant leap from the previous 2Ah prototype, representing a 25-fold increase in capacity. Purdy highlighted the importance of scaling up production to meet industry requirements. "We need to make sure that we've got reproducibility. What industry needs is not just a few successful cells but large-scale, reliable production," he said. Ilika has benefited from £2.8 million in grant funding through the Faraday Battery Challenge, which Purdy noted has effectively doubled the impact of investor funding. In parallel, Ilika has also demonstrated its manufacturing process at a giga-scale setting through a partnership with the UK Battery Industrialisation Centre (UKBIC). Looking ahead, the company plans to complete its 1.5MWh per year pilot line with automated equipment. Key upcoming milestones include releasing P1.5 prototypes in the summer and the full P2 release by year-end. Stay tuned for more updates on Ilika’s Goliath program. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates. #IlikaPLC #EVBatteries #SolidStateBatteries #BatteryTechnology #EnergyStorage #RenewableEnergy #ElectricVehicles #BatteryInnovation #TechInvesting #ProactiveInvestors